📄 medicine

SEMA-RENAL: Real-World Effects of Subcutaneous Semaglutide on Kidney Outcomes

In a real-world cohort of patients with type 2 diabetes, subcutaneous semaglutide was associated with sustained reductions in albuminuria and stable kidney function over 12 months, supporting its role as a beneficial adjunct in managing chronic kidney disease.

Original authors: Khai Vern Poon, Shing Shen Bay, Yiu Wayn Ker, Wan Nadrah Wan Mohd Zakri, Wan Ahmad Hafiz Wan Md Ad

Published 2026-06-28

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Khai Vern Poon, Shing Shen Bay, Yiu Wayn Ker, Wan Nadrah Wan Mohd Zakri, Wan Ahmad Hafiz Wan Md Ad

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The Big Picture: A "Kidney Check-Up" for a New Diabetes Drug

Imagine the kidneys as a highly sophisticated coffee filter in your body. Their job is to clean your blood, keeping good stuff in and letting waste flow out. In people with Type 2 diabetes, this filter can get clogged or damaged, causing "leaks" where valuable protein spills out into the urine (a sign of kidney trouble).

Doctors already have a "four-pillar" strategy to protect these filters:

RAS Blockers: Like tightening a valve to reduce pressure.
SGLT2 Inhibitors: Like a specialized cleaning crew.
Newer Meds: Other protective tools.
GLP-1 Agonists (Semaglutide): The new tool being tested in this study.

This study asked a simple question: If we add Semaglutide (a popular diabetes injection) to a patient's routine, does it help the kidney filter stop leaking, and does it keep the filter working well over time?

The Experiment: A Real-World Look

Instead of a strict, controlled lab experiment, the researchers looked at 154 real patients at the University Malaya Medical Centre. These were people with Type 2 diabetes (many also had existing kidney issues) who started taking Semaglutide injections between January and December 2025.

The researchers checked their "kidney health reports" at three times:

Before starting (Baseline)
6 months later
12 months later

Most of these patients were already taking the other "kidney protection" medicines mentioned above. The study wanted to see if Semaglutide offered any extra help on top of that.

What Happened? (The Results)

1. The "Leak" Stopped (Albuminuria Reduced)

Think of protein in the urine as water leaking out of a cracked pipe.

The Result: The study found that the "leak" got significantly smaller. At 6 months, the leak was reduced, and by 12 months, it was even smaller.
The Analogy: It's like patching a hole in a boat. The water (protein) stopped pouring in as fast. This is a very good sign for kidney health.
Who benefited most? Patients who already had kidney disease (CKD) saw the biggest improvement in stopping the leak.

2. The Filter's Speed Stayed Steady (eGFR Stability)

Think of eGFR (a measure of how fast the filter works) as the speedometer of the kidney.

The Result: The speedometer didn't drop much. For the first 6 months, the speed was almost exactly the same as when they started. At 12 months, there was a tiny, barely noticeable drop, but it wasn't a big deal.
The Analogy: Usually, in people with diabetes, the kidney speedometer slowly ticks down over years. In this study, Semaglutide helped the patients hold their ground. They didn't get worse; they stayed stable.

3. The Side Benefits (Weight and Sugar)

While the main goal was kidney health, the "side effects" were actually positive:

Sugar Control (HbA1c): Dropped significantly.
Weight: Patients lost weight steadily over the year.
Blood Pressure: Dropped a little bit in the first 6 months, but the effect faded by month 12.

The Mystery of the "Predictors"

The researchers tried to figure out who got the best kidney results. They ran a statistical "detective game" and found two surprising clues:

Having Kidney Disease (CKD) helped: Patients who already had kidney issues were more likely to see a big reduction in the "leak" than those with healthy kidneys.
Starting with a "faster" filter helped: Patients who started with higher kidney function were more likely to see the leak stop.

What didn't matter? Surprisingly, how much weight they lost or how much their blood sugar dropped didn't directly predict whether their kidneys would improve. This suggests Semaglutide might be helping the kidneys through a secret backdoor (direct kidney action), not just by fixing sugar and weight.

The "Teamwork" Effect

The study also looked at whether taking SGLT2 inhibitors (another kidney drug) alongside Semaglutide made a difference.

The Finding: Patients taking both drugs saw a very steady, long-term reduction in the "leak." Patients taking only Semaglutide saw a reduction at 6 months, but it wasn't as strong or lasting at 12 months.
The Analogy: It's like having two mechanics working on a car. When both are there, the repair lasts longer. When only one is there, the fix is good for a while but might fade.

The Bottom Line

In simple terms:

Did Semaglutide help kidneys? Yes. It stopped the "leak" (protein in urine) and kept the kidney speedometer stable for a full year.
Is it a magic cure? No. It works best when added to the existing "team" of kidney medicines.
Who should care? People with Type 2 diabetes, especially those who already have some kidney damage, might find this drug very useful as an extra layer of protection.

Important Note: This was a look back at real-world data, not a new controlled trial. While the results are promising, the authors say we need bigger, longer studies to be 100% sure about the long-term effects. But for now, it looks like Semaglutide is a strong teammate in the fight to protect kidneys.

Technical Summary: SEMA-RENAL Study

Problem Statement
While Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, are established for cardiovascular risk reduction in type 2 diabetes, real-world data regarding their specific effects on kidney outcomes remain limited. Although large cardiovascular outcome trials have reported renal benefits as secondary endpoints, there is a paucity of evidence characterizing the longitudinal impact of subcutaneous semaglutide on renal parameters—specifically estimated glomerular filtration rate (eGFR) and albuminuria—within routine clinical practice. This study addresses the need to define the role of semaglutide within the contemporary "four pillars" of kidney protection (RAS inhibition, SGLT2 inhibitors, ns-MRAs, and GLP-1 RAs), particularly in patients with type 2 diabetes with or without chronic kidney disease (CKD).

Methodology
The study, titled SEMA-RENAL, is a retrospective cohort study conducted at the University Malaya Medical Centre (UMMC) involving 154 adults initiated on subcutaneous semaglutide between January and December 2025.

Population: The cohort included patients with type 2 diabetes (93.5%), with a high burden of CKD (68.2%). Most patients were already receiving background renoprotective therapy, including RAS blockers (76.6%) and SGLT2 inhibitors (77.9%).
Data Collection: Renal and metabolic parameters were extracted from electronic medical records at baseline, 6 months, and 12 months.
Statistical Analysis:
- Continuous variables (eGFR, uACR, HbA1c, weight, SBP) were analyzed using the Wilcoxon signed-rank test due to non-normal distribution.
- Multivariable logistic regression was employed to identify independent predictors of achieving a ≥30% reduction in urinary albumin–creatinine ratio (uACR).
- Subgroup analyses were performed based on CKD status and concomitant SGLT2 inhibitor use.
- Data cleaning involved standardizing mixed-unit strings and handling missing follow-up data via a complete-case approach for specific timepoints.

Key Results

Albuminuria (Primary Outcome): Semaglutide initiation was associated with a significant and sustained reduction in uACR. Median uACR decreased from a baseline of 11.1 mg/mmol to 6.9 mg/mmol at 6 months ( $p < 0.001$ ) and further to 5.0 mg/mmol at 12 months ( $p = 0.001$ ). The reduction was more pronounced in patients with pre-existing CKD.
Kidney Function (eGFR): eGFR remained largely stable at 6 months. At 12 months, a small but statistically significant change was observed ( $p = 0.002$ ), which the authors note was not clinically meaningful and likely reflected underlying disease progression rather than drug-induced harm.
Metabolic and Hemodynamic Parameters: Significant improvements were observed in HbA1c (reduced from 8.3% to 6.8%) and body weight (reduced from 82.0 kg to 77.3 kg) at both 6 and 12 months ( $p < 0.001$ ). Systolic blood pressure showed a modest reduction at 6 months but was not significantly different at 12 months.
Predictors of Response: Multivariable analysis identified higher baseline eGFR and the presence of CKD as independent predictors of achieving a ≥30% reduction in uACR at both 6 and 12 months. Conversely, glycemic control (HbA1c), body weight, and concomitant SGLT2 inhibitor use were not independent predictors of this specific renal response in the adjusted model.
Concomitant Therapy: Patients on background SGLT2 inhibitors demonstrated sustained within-group uACR reductions at 12 months, whereas those not on SGLT2 inhibitors showed a reduction at 6 months that was not sustained at 12 months, though between-group differences did not reach statistical significance.

Key Contributions

Real-World Evidence: The study provides real-world data confirming that semaglutide is associated with sustained albuminuria reduction and kidney function preservation over 12 months in a cohort with a high burden of CKD, complementing existing trial data.
Additive Benefit: It demonstrates that semaglutide offers renoprotective benefits (specifically proteinuria reduction) even when added to optimized background therapy including RAS blockade and SGLT2 inhibitors.
Predictive Factors: The identification of CKD status and baseline eGFR as predictors for proteinuria response helps stratify which patients may derive the most significant renal benefit from the therapy.
Safety Profile: The study reinforces the safety of semaglutide regarding eGFR stability, showing no clinically meaningful decline in kidney function over the study period.

Significance and Claims
The authors claim that these findings support the use of subcutaneous semaglutide as a useful adjunct within a multifactorial approach to CKD management for patients with type 2 diabetes. The study suggests that the renal benefits of semaglutide extend beyond its glucose-lowering and weight-loss effects, potentially involving direct renal mechanisms such as anti-inflammatory properties and modulation of intraglomerular hemodynamics.

The paper concludes that while the observed reduction in albuminuria and stability of eGFR are encouraging, the findings are modest and derived from a retrospective design. Therefore, the authors assert that these results justify further prospective studies with kidney outcomes as primary endpoints to confirm long-term benefits. They emphasize that in the context of the high prevalence of diabetes and CKD in Malaysia, such data is valuable for identifying patient subgroups (specifically those with established CKD) who are most likely to benefit, potentially guiding more targeted and cost-effective therapeutic strategies.